🎓 30 Jan 2026 Dr. Ahsen Kartal Özcan earned her doctorate. →🔬 28 Jan 2026 Project IMBAS and the TOBB ETÜ Acoustics Laboratory launched. →📝 19 Jan 2026 New scientific article: Extended high-frequency hearing assessments. →🎙 27 Dec 2025 Interview: The color of sound and the harmony of science, with Öğütnaz Çoban. →🧠 9 Nov 2025 Our brain modulates auditory processing while walking. →🎧 Podcast Kulağına Küpe Audiology is live on Spotify. →📊 ODAK 62 audiological assessment tools under one roof. →
Home / ODAK / Khalfa Hyperacusis Questionnaire
Questionnaire/ScaleAdaptationOpen access

Khalfa Hyperacusis Questionnaire

Khalfa Hiperakuzi Ölçeği
HyperacusisDecreased Sound Tolerance
Corresponding author: Murat Erinç

Description

Developed to assess individuals’ sensitivity to sounds, the Khalfa Hyperacusis Questionnaire is a 14-item self-report tool comprising attentional, social and emotional dimensions. Its Turkish adaptation provides a valid and reliable assessment for the diagnosis of hyperacusis.

Measured Properties

Hyperacusis (auditory over-sensitivity)

Target Population

General adult population (18 years and older), individuals with hyperacusis complaints, individuals who have developed sensitivity to noise

Source & Citation

Erinc, M., & Derinsu, U. (2020). Turkish Adaptation of Khalfa Hyperacusis Questionnaire. Medeniyet Medical Journal, 35(2), 142. http://10.5222/MMJ.2020.97947
Go to source ↗

Original Scale

Original name: Khalfa Hyperacusis Questionnaire

Khalfa, S., Dubal, S., Veuillet, E., Perez-Diaz, F., Jouvent, R., & Collet, L. (2002). Psychometric normalization of a hyperacusis questionnaire. ORL; journal for oto-rhino-laryngology and its related specialties, 64(6), 436–442. https://doi.org/10.1159/000067570
Go to original source ↗

Access & Download

This tool is open access. You can download it directly from the links below.

Similar tools

Questionnaire/Scale

Misophonia Questionnaire

← PreviousAuditory Localization Questionnaire (ALQ)Next →Cochlear Implant Quality of Life Instruments (CIQOL-35 & CIQOL-10)